KR102645426B1 - Method of providing automated platform service for reporting processing of sales and expenditure resolutions by user for pharmaceutical distribution - Google Patents

Abstract

According to one embodiment, a device receives a sales request including drug information from a pharmaceutical company's terminal, generates CSO matching information for business activities of the drug based on the drug information, and sends the CSO matching information to the CSO's terminal. Provide drug information, provide drug information to customer terminals, including hospitals and pharmacies, receive drug order information from the customer company terminal, provide the received order information to the pharmaceutical company terminal, and respond to the order information. When the delivery of the medicine is completed, the fee for the CSO can be determined, expenditure information can be created based on the medicine information, order information, and fee information, and the expenditure information can be registered.

Description

Method of providing automated platform service for reporting processing of sales and expenditure resolutions by user for pharmaceutical distribution

The embodiments below relate to technology that provides an automated platform service for reporting processing of sales and expenditure resolutions for each user for pharmaceutical distribution.

The pharmaceutical industry refers to an industry that researches and manufactures medicines, including herbal medicine, for the purpose of diagnosing and treating, alleviating, treating, preventing, or promoting health of various diseases in humans or animals.

The existing method of pharmaceutical companies selecting salespeople to sell products resulted in a large burden of sales and administrative expenses and labor costs, and problems such as deviation of internal employees occurred. Accordingly, pharmaceutical companies are increasingly entrusting sales agency work to sales agencies (CSOs), including individual business owners, and sales are determined based on the number of salespeople and capabilities of the sales agency that carries out the sales.

Accordingly, various online systems are being developed for the sale and management of various medicines, but the development of a platform to manage the distribution and sales activities of medicines is insufficient in preparation for the revision of the CSO-related law.

Republic of Korea Patent No. 10-2108489 (announced on May 7, 2020) Republic of Korea Patent No. 10-2287965 (announced on August 9, 2021) Republic of Korea Patent No. 10-2274492 (announced on July 8, 2021) Republic of Korea Patent Publication No. 10-2023-0118751 (published on August 14, 2023)

Embodiments seek to provide an automated platform service for reporting processing of sales and expenditure resolutions for each user for pharmaceutical distribution.

Embodiments seek to generate matching information between pharmaceutical companies and CSOs based on drug information and the CSO's drug sales history.

Embodiments are intended to automatically generate a pharmaceutical contract based on ordering information and provide it to the pharmaceutical company.

According to one embodiment, the method performed by the device includes receiving a business request including drug information from a pharmaceutical company terminal and generating CSO matching information for business activities of the drug based on the drug information; Providing the drug information to the terminal of the CSO corresponding to the CSO matching information; Providing the drug information to terminals of customer companies including hospitals and pharmacies; Receiving pharmaceutical order information from the customer company's terminal; Providing the received order information to the pharmaceutical company's terminal; When delivery of the medicine corresponding to the order information is completed, determining a fee for the CSO; And it may include generating expenditure information based on the drug information, the ordering information, and the information on the fee, and registering the expenditure information.

The step of generating the CSO matching information includes confirming the ingredients included in the medicine for each pharmaceutical company from the medicine information, and determining as the main ingredient the ingredient that satisfies preset standards among the ingredients contained in the medicine. Obtaining pharmaceutical sales history from the CSO's terminal, confirming the ingredients and effects of ingredients of pharmaceuticals of pharmaceutical companies with which the CSO has a business history from the pharmaceutical sales history, and the main ingredients among the pharmaceuticals included in the pharmaceutical sales history Calculating a similar business ratio, which is the ratio of drugs with similar ingredients containing ingredients for the same purpose as the effect of the main ingredient, the amount of business expenditures spent on business activities and sales success from the business history of the medicine Checking the number of times, calculating the sales price by dividing the number of sales successes from the sales expenditure amount, checking the pharmaceutical company's sales budget from the pharmaceutical company's terminal, calculating the difference between the sales budget and the sales unit price. Accordingly, determining the number of drugs available for business among drugs containing the above-mentioned main ingredients, determining the business index of the CSO based on the similar sales ratio, sales unit price, and number of drugs available for business, And it may include generating CSO matching information based on the sales index.

In the step of providing the received ordering information to the pharmaceutical company's terminal, the step further includes generating a drug contract based on the ordering information and providing the generated drug contract along with the ordering information to the pharmaceutical company's terminal. can do.

The step of creating the pharmaceutical contract includes confirming information on the drug to be ordered from the ordering information, obtaining contact details of the customer company including the ordering information, and retrieving information on the drug to be ordered from the contact details. Thus, checking the information of the pharmaceutical company corresponding to the ordering information, checking whether there is an existing transaction with the pharmaceutical company corresponding to the drug to be ordered from the contact history, and if there is no existing transaction with the pharmaceutical company, Extracting the stored standard contract form, generating a pharmaceutical contract using the information of the drug to be ordered and the pharmaceutical company's information in the standard contract form, if there is an existing transaction with the pharmaceutical company, from the contact details Extracting a contract form, generating a pharmaceutical contract using the information of the drug to be ordered and the pharmaceutical company's information in the existing contract form, comparing the existing contract form with the standard contract form, and generating the contract form. It may include the step of displaying parts that are different from the existing contract form and the standard contract form according to the comparison results in the pharmaceutical contract form in a first color, and marking common parts in a second color different from the first color.

The method performed by the device further includes the step of modifying the drug contract when additional ordering information for the drug is received from the customer company's terminal, and the step of modifying the drug contract includes the ordering information and the additional drug contract. It may include comparing ordering information, and modifying the drug contract based on a comparison result of the ordering information.

The step of registering the expenditure information includes extracting a pre-stored expenditure report form, applying the expenditure information to the extracted expenditure report form to create an expenditure report, obtaining information on laws on drug distribution, and , classifying the first law currently in effect and the second law scheduled to be implemented among the laws, the first law and the prepared expenditure report to a large language model (LLM) trained in advance to update the expenditure report based on the law. A step of inputting and outputting a first expenditure report, inputting the second law and the prepared expenditure report into a large language model (LLM) previously trained to update the expenditure report based on the law and outputting a second expenditure report. , displaying the expenditure report in a first area of the screen of the CSO's terminal, displaying the first expenditure report in a second area, and displaying the second expenditure report in a third area, wherein the expenditure report, marking different parts of the first expenditure report and the second expenditure report in different colors, wherein when any one of the colored parts in the first expenditure report is selected, the selected part of the first law Extracting the relevant law and displaying it in a pop-up form in the second area, when any one of the colored parts in the second expenditure report is selected, the law corresponding to the selected part of the second law is displayed. extracting and displaying the expenditure information in a pop-up form in the third area, and confirming a storage period of the expenditure information based on the law, and according to the storage period the expenditure report, the first expenditure report and the second expenditure report. It may include the step of storing expenditure information including.

The method performed by the device includes obtaining order details including the order information from the terminal of the CSO; Generating an ordering report based on the ordering information, pharmaceutical company information, and drug information included in the ordering details, inserting and uploading a differently generated security phrase for each ordering report; When one of the uploaded order reports is selected from the pharmaceutical company's terminal, displaying an order report with values included in the order report modified to be within a preset range; Collecting uploaded order reports during a preset period, and determining whether there are leaked order reports among the collected order reports with overlapping security phrases or similar numerical values within a preset range; And if the leaked order report exists, it may further include providing a leakage notification to the CSO's terminal.

The device according to one embodiment may be combined with hardware and controlled by a computer program stored in a medium to execute any one of the above-described methods.

Embodiments may provide an automated platform service for processing user-specific sales and expenditure resolution reports for pharmaceutical distribution.

Embodiments may generate matching information between a pharmaceutical company and a CSO based on drug information and the CSO's drug sales history.

Embodiments may automatically generate a pharmaceutical contract based on ordering information and provide it to the pharmaceutical company.

Embodiments can help CSOs more appropriately perform legally required reporting and sales activities and enhance legal compliance.

1 is a diagram for explaining the configuration of a system according to an embodiment.
Figure 2 is a flowchart illustrating the process of providing an automated platform service for reporting processing of sales and expenditure resolutions for each user for drug distribution according to an embodiment.
Figure 3 is a flowchart for explaining the process of generating CSO matching information according to an embodiment.
Figure 4 is a flowchart explaining the process of creating a pharmaceutical contract according to an embodiment.
Figure 5 is a flowchart explaining the process of modifying a pharmaceutical contract according to an embodiment.
Figure 6 is a flowchart for explaining the process of registering expenditure information according to an embodiment.
Figure 7 is a flow chart to explain a process for providing a notification of leakage of an order report according to an embodiment.
Figure 8 is an exemplary diagram of the configuration of a device according to an embodiment.

Hereinafter, embodiments will be described in detail with reference to the attached drawings. However, various changes can be made to the embodiments, so the scope of the patent application is not limited or limited by these embodiments. It should be understood that all changes, equivalents, or substitutes for the embodiments are included in the scope of rights.

Specific structural or functional descriptions of the embodiments are disclosed for illustrative purposes only and may be modified and implemented in various forms. Accordingly, the embodiments are not limited to the specific disclosed form, and the scope of the present specification includes changes, equivalents, or substitutes included in the technical spirit.

Terms such as first or second may be used to describe various components, but these terms should be interpreted only for the purpose of distinguishing one component from another component. For example, a first component may be named a second component, and similarly, the second component may also be named a first component.

When a component is referred to as being “connected” to another component, it should be understood that it may be directly connected or connected to the other component, but that other components may exist in between.

The terms used in the examples are for descriptive purposes only and should not be construed as limiting. Singular expressions include plural expressions unless the context clearly dictates otherwise. In this specification, terms such as “comprise” or “have” are intended to designate the presence of features, numbers, steps, operations, components, parts, or combinations thereof described in the specification, but are not intended to indicate the presence of one or more other features. It should be understood that this does not exclude in advance the possibility of the existence or addition of elements, numbers, steps, operations, components, parts, or combinations thereof.

Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by a person of ordinary skill in the technical field to which the embodiments belong. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related technology, and unless explicitly defined in the present application, should not be interpreted in an ideal or excessively formal sense. No.

In addition, when describing with reference to the accompanying drawings, identical components will be assigned the same reference numerals regardless of the reference numerals, and overlapping descriptions thereof will be omitted. In describing the embodiments, if it is determined that detailed descriptions of related known technologies may unnecessarily obscure the gist of the embodiments, the detailed descriptions are omitted.

Embodiments may be implemented in various types of products such as personal computers, laptop computers, tablet computers, smart phones, televisions, smart home appliances, intelligent vehicles, kiosks, and wearable devices.

In the present invention, artificial intelligence (AI) refers to technology that imitates human learning ability, reasoning ability, perception ability, etc. and implements this with a computer, and includes concepts such as machine learning and symbolic logic. may include. Machine Learning (ML) is an algorithmic technology that classifies or learns the characteristics of input data on its own. Artificial intelligence technology is a machine learning algorithm that analyzes input data, learns the results of the analysis, and makes judgments or predictions based on the results of the learning. Additionally, technologies that mimic the functions of the human brain, such as cognition and judgment, using machine learning algorithms can also be understood as the category of artificial intelligence. For example, technical fields such as verbal understanding, visual understanding, reasoning/prediction, knowledge representation, and motion control may be included.

Machine learning can refer to the process of training a neural network model using experience processing data. Machine learning can mean that computer software improves its own data processing capabilities. A neural network model is built by modeling the correlation between data, and the correlation can be expressed by a plurality of parameters. A neural network model extracts and analyzes features from given data to derive correlations between data. Repeating this process to optimize the parameters of the neural network model can be called machine learning. For example, a neural network model can learn the mapping (correlation) between input and output for data given as input-output pairs. Alternatively, a neural network model may learn the relationships by deriving regularities between given data even when only input data is given.

An artificial intelligence learning model or neural network model may be designed to implement the human brain structure on a computer, and may include a plurality of network nodes with weights that simulate neurons of a human neural network. A plurality of network nodes may have a connection relationship with each other by simulating the synaptic activity of neurons in which neurons exchange signals through synapses. In an artificial intelligence learning model, multiple network nodes are located in layers of different depths and can exchange data according to convolutional connection relationships. The artificial intelligence learning model may be, for example, an artificial neural network model (Artificial Neural Network), a convolution neural network (CNN) model, etc. As an example, an artificial intelligence learning model may be machine-learned according to methods such as supervised learning, unsupervised learning, and reinforcement learning. Machine learning algorithms for performing machine learning include Decision Tree, Bayesian Network, Support Vector Machine, Artificial Neural Network, and Ada-boost. , Perceptron, Genetic Programming, Clustering, etc. can be used.

Among them, CNN is a type of multilayer perceptrons designed to use minimal preprocessing. CNN consists of one or several convolution layers and general artificial neural network layers on top of them, and additionally utilizes weights and pooling layers. Thanks to this structure, CNN can fully utilize input data with a two-dimensional structure. Compared to other deep learning structures, CNN shows good performance in both video and audio fields. CNNs can also be trained via standard back propagation. CNNs have the advantage of being easier to train and using fewer parameters than other feedforward artificial neural network techniques.

Convolutional networks are neural networks that contain sets of nodes with bound parameters. The increasing size of available training data and the availability of computational power, combined with algorithmic advances such as piecewise linear unit and dropout training, have led to significant improvements in many computer vision tasks. For extremely large data sets, such as those available for many tasks today, overfitting is not critical, and increasing the size of the network improves test accuracy. Optimal use of computing resources becomes a limiting factor. For this purpose, distributed, scalable implementations of deep neural networks can be used.

1 is a diagram for explaining the configuration of a system according to an embodiment.

The system according to one embodiment may include a CSO terminal 10, a customer company terminal 20, a pharmaceutical company terminal 30, and a device 40 that can communicate with each other through a communication network.

First, a communication network can be configured regardless of the communication mode, such as wired or wireless, and can be implemented in various forms to enable communication between servers and between servers and terminals.

The CSO's terminal 10 may be a terminal used by a user who wishes to use the automated platform service for reporting processing of sales and expenditure resolutions for each user for drug distribution.

CSO (Contract Sales Organization) is a company that conducts sales. In the present invention, CSO may refer to an employee of a CSO company entrusted with sales promotion of pharmaceuticals and medical devices.

The CSO's terminal 10 may be a desktop computer, laptop, tablet, smartphone, etc. For example, as shown in FIG. 1, the CSO's terminal 10 may be a smartphone, and may be employed differently depending on the embodiment.

Here, the automated platform service for reporting processing of sales and spending resolutions by user for drug distribution may include a service that automates reporting processing for sales and spending resolutions for each CSO company for drug distribution, and the platform service may include the pharmaceutical company's drugs. It may include, but is not limited to, services such as list provision, drug ordering, drug supply, drug sales activities, drug delivery, transaction statement management, settlement and collection details for each pharmaceutical company, order and delivery inquiry, drug promotion, and supporting documentation. It may further include a series of administrative services required in the pharmaceutical distribution process.

The CSO's terminal 10 may be configured to perform all or part of the calculation function, storage/reference function, input/output function, and control function of a typical computer. The CSO's terminal 10 may be configured to communicate with the device 40 wired or wirelessly.

The CSO's terminal 10 is connected to a web page operated by a person or organization providing services using the device 40, or an application developed and distributed by a person or organization providing services using the device 40. This can be installed. The CSO's terminal 10 may be linked with the device 40 through a web page or application.

The CSO's terminal 10 can access the device 40 through a web page or application provided by the device 40.

The customer company's terminal 20 may be a terminal used by an employee of the customer company who wishes to purchase medicines. For example, customer companies may include, but are not limited to, hospitals and pharmacies that wish to prescribe and sell medicines. The customer's terminal 20 may be a desktop computer, laptop, tablet, smartphone, etc. For example, as shown in FIG. 1, the customer company's terminal 20 may be a smartphone and may be employed differently depending on the embodiment.

The customer's terminal 20 may be configured to perform all or part of the calculation function, storage/reference function, input/output function, and control function of a typical computer. The customer's terminal 20 may be configured to communicate with the device 40 in a wired or wireless manner.

The customer's terminal 20 is connected to a web page operated by a person or organization providing services using the device 40, or an application developed and distributed by a person or organization providing services using the device 40. This can be installed. The customer company's terminal 20 may be linked to the device 40 through a web page or application.

The customer company's terminal 20 can access the device 40 through a web page or application provided by the device 40.

The pharmaceutical company's terminal 30 may be a terminal used by workers at a pharmaceutical company that wants to manufacture and sell pharmaceutical products. Pharmaceutical companies can manufacture drugs and entrust sales activities to sell drugs to CSO companies. The pharmaceutical company's terminal 30 may be a desktop computer, laptop, tablet, smartphone, etc. For example, as shown in FIG. 1, the pharmaceutical company's terminal 30 may be a smartphone and may be employed differently depending on the embodiment.

The pharmaceutical company's terminal 30 may be configured to perform all or part of the calculation function, storage/reference function, input/output function, and control function of a typical computer. The pharmaceutical company's terminal 30 may be configured to communicate with the device 40 wired or wirelessly.

The pharmaceutical company's terminal 30 is connected to a web page operated by a person or organization providing services using the device 40, or an application developed and distributed by a person or organization providing services using the device 40. This can be installed. The pharmaceutical company's terminal 30 may be linked to the device 40 through a web page or application.

The pharmaceutical company's terminal 30 can access the device 40 through a web page or application provided by the device 40.

The singular expressions recited in the claims may be understood to include the plural. For example, the drug in a claim may refer to one drug or two or more drugs.

The device 40 can provide an automated platform service for reporting processing of sales and expenditure resolutions for each user for pharmaceutical distribution.

The device 40 may be an own server owned by a person or organization that provides services using the device 40, a cloud server, or a p2p (peer-to-peer) collection of distributed nodes. It may be possible. The device 40 may be configured to perform all or part of the calculation function, storage/reference function, input/output function, and control function of a typical computer.

The device 40 may be configured to communicate wired or wirelessly with the CSO's terminal 10, the customer company's terminal 20, and the pharmaceutical company's terminal 30, and can communicate with the CSO's terminal 10, the customer company's terminal 20, and the pharmaceutical company. It is possible to control the operation of the terminal 30 and control what information is displayed on the screen of the CSO's terminal 10, the customer company's terminal 20, and the pharmaceutical company's terminal 30.

Meanwhile, for convenience of explanation, only the CSO's terminal 10, the customer company's terminal 20, and the pharmaceutical company's terminal 30 are shown in FIG. 1, but the number of terminals may vary depending on the embodiment. There are no particular restrictions on the number of terminals and the number of printer devices as long as the processing capacity of the device 40 allows.

According to one embodiment, a database may be provided within the device 40, but the present invention is not limited to this, and the database may be configured separately from the device 40. Device 40 may include multiple artificial neural networks for performing machine learning algorithms.

In the revised Pharmaceutical Affairs Act, CSOs began to appear under the name of “drug promotional business operators,” a reporting system for pharmaceutical promotional business operators (scheduled to be implemented on October 19, 2024), and the provision of rebates through pharmaceutical promotional business operators is prohibited (October 19, 2024). New systems are scheduled to be implemented one after another, including mandatory company registration and disclosure of expenditure reports (to be implemented on July 21, 2023).

The “Reasons for Amendment” of the Amendment Act states as follows:

“Current law prohibits drug suppliers from providing economic benefits such as money, goods, or benefits for the purpose of promoting sales, and obliges them to prepare and keep expenditure reports on the details of provision of economic benefits, etc. However, it has been pointed out that there is a limit to achieving the purpose of the legislation because there is insufficient basis for regulating the provision of economic benefits to pharmacists, medical personnel, medical institution founders, etc. by companies that have entered into consignment contracts for sales promotion work with pharmaceutical suppliers. Accordingly, the purpose is to strengthen pharmaceutical distribution management by stipulating that not only pharmaceutical suppliers but also those entrusted with the sales promotion of pharmaceutical products are prohibited from providing economic benefits and adding them to the list of persons obligated to prepare expenditure reports, while making expenditure reports public and strengthening the penalties applied in case of violation. .”

In other words, the revision of the Pharmaceutical Affairs Act was intended to strengthen the monitoring, regulation, and punishment of CSOs that act as promotional sales agents for the same reasons as previously regulating drug suppliers (pharmaceutical companies and wholesalers).

Accordingly, CSOs must report to cities, counties, and districts in accordance with the Ordinance of the Ministry of Health and Welfare, and pharmaceutical companies must not entrust the task of promoting drug sales to CSOs that have not reported. In addition, when sales promotion work is entrusted (including re-consignment), a consignment contract must be drawn up and supporting data must be kept for 5 years. If the Minister of Health and Welfare requests a promotional business operator to submit a consignment contract and related evidence, he/she must comply unless there is a justifiable reason.

With the revision to CSO, regulations on pharmaceutical sales have been strengthened, raising concerns about a decline in pharmaceutical sales activities. According to one embodiment, the device 40 resolves difficulties caused by the CSO amendment and provides business convenience such as sales and logistics by supporting various tasks such as submitting legal reports on the CSO's business activities for medical and pharmaceutical products of pharmaceutical companies. We can provide platform services that can be used.

Figure 2 is a flowchart illustrating the process of providing an automated platform service for reporting processing of sales and expenditure resolutions for each user for drug distribution according to an embodiment.

Referring to FIG. 2, first, in step S201, the device 40 receives a business request including drug information from the pharmaceutical company's terminal 30, and provides CSO matching information for drug sales activities based on the drug information. can be created.

The device 40 may receive a business request from the pharmaceutical company's terminal 30 stating that it entrusts drug information and sales and business activities of the drug to the CSO for which the CSO is to be sold.

For example, drug information includes product name, pharmaceutical company name, administration route, Ministry of Food and Drug Safety classification, KPI drug efficacy classification, main ingredient code, ingredient name, and efficacy effect of medicines manufactured by pharmaceutical companies and medicines for which pharmaceutical companies wish to entrust sales and sales activities to CSO. , may include, but is not limited to, information on drug codes, dosage forms, narcotics, AIC codes, inventory of drugs held by the manufacturer, distribution methods, etc.

The device 40 may receive drug information from the pharmaceutical company's terminal 10 and store the drug information and sales request in a database by matching them with the pharmaceutical company.

At this time, a detailed description of the process of generating CSO matching information will be described later with reference to FIG. 3.

The device 40 receives information on drugs for which the pharmaceutical company wishes to entrust sales and sales activities to the CSO, and generates matching information for the CSO for drug sales activities based on the pharmaceutical company's drug information, so that the pharmaceutical company distributes and distributes the drug. You can effectively select a CSO to carry out related sales activities.

In step S202, the device 40 may provide drug information to the terminal 10 of the CSO corresponding to the CSO matching information.

The device 40 generates CSO matching information containing information about the CSO in charge of sales and sales activities of the pharmaceutical company's drugs, and the CSO performs sales and sales activities through the terminal 10 of the CSO corresponding to the CSO matching information. You can transmit drug information from the pharmaceutical company in charge.

The device 40 provides drug information to the CSO's terminal 10 corresponding to the CSO matching information, allowing the CSO company to provide information to carry out sales and sales activities for drugs based on the drug information.

In step S203, the device 40 may receive drug order information from the customer company's terminal 20.

The device 40 provides pharmaceutical company drug information to the CSO terminal 10 corresponding to CSO matching information, and based on the drug information, the CSO company targets customer companies including hospitals and pharmacies that prescribe and sell drugs. It is possible to carry out sales and sales activities of pharmaceuticals.

The device 40 may receive drug order information from the customer company's terminal 20 after the CSO company conducts business and sales activities for the drug product targeting the customer company.

At this time, the ordering information of the drug is information necessary to order the drug, for example, drug information, order quantity, unit price, ordering date, delivery deadline, pharmaceutical company information, cost according to ordering, payment information, and other information required to place an order. It may include information about contact details, etc., but is not limited to this.

At this time, contact details for placing an order may include, but are not limited to, information about email details, call records, text message details, etc.

The device 40 may receive drug order information from the customer company's terminal 20 and store the drug order information received from the customer company's terminal 20 in a database.

In step S204, the device 40 may provide the received order information to the pharmaceutical company's terminal 30.

The device 40 provides order information received from the customer company's terminal 20 to the pharmaceutical company's terminal 30, allowing the customer company to order the desired drug and the pharmaceutical company to process the order information.

In step S205, the device 40 may determine the fee for the CSO when delivery of the medicine corresponding to the order information is completed.

The device 40 allows the pharmaceutical company to deliver medicines according to order information to the customer company and receive from the customer company's terminal 20 whether delivery of the medicines has been completed. When delivery of the drug corresponding to the order information is completed, the device 40 may determine a fee for the CSO as compensation for business and sales activities of the drug.

For example, the device 40 verifies the quantity and sales profit of medicines sold from the ordering information, obtains ordering details including the ordering information of the CSO from the database, and determines the ordering details of the medicines ordered through the CSO company from the ordering details. You can receive information on the number of successful orders and the sales period required to successfully place a customer's order through sales activities.

According to one embodiment, the device 40 determines the commission in proportion to the quantity of medicines sold and sales profits, and applies a weight determined to the commission as the number of successful orders increases and the sales period is short, so that the CSO Fees can be determined. At this time, the process of determining the fee for CSO is only an example, and is not limited to this, and may be set differently depending on the embodiment.

In step S206, the device 40 may generate expenditure information based on information on drug information, order information, and fees, and register the expenditure information. At this time, a detailed description of the process of registering expenditure information will be described later with reference to FIG. 6.

Figure 3 is a flowchart for explaining the process of generating CSO matching information according to an embodiment.

Referring to FIG. 3, first, in step S301, the device 40 checks the ingredients included in the medicine for each pharmaceutical company from the medicine information, and among the ingredients, the ingredient that satisfies the preset standards is selected as the main ingredient. You can decide. At this time, the preset standard may be set differently depending on the embodiment.

The device 40 can check the ingredients included in the medicine for each pharmaceutical company from the medicine information, and determine as the main ingredient the ingredient that satisfies preset standards among the medicines manufactured by the pharmaceutical company.

For example, the device 40 checks the ingredients contained in the medicine sold by pharmaceutical company A, and if ingredient a among the ingredients of the medicine sold by pharmaceutical company A satisfies the preset standard, it selects ingredient a as the main ingredient of the medicine sold by pharmaceutical company A. It can be determined by ingredients.

In step S302, the device 40 may obtain pharmaceutical sales history from the CSO's terminal 10.

The device 40 may obtain pharmaceutical sales history from the CSO's terminal 10, match the obtained pharmaceutical sales history with the CSO, and store it in a database.

At this time, the pharmaceutical sales history may include information on the sales and sales activities performed by the CSO and the performance of sales and sales activities. For example, the pharmaceutical sales history may include the pharmaceuticals for which sales and sales activities were performed. It may include information on the sales quantity of pharmaceuticals, sales amount, sales date, sales period, commission, sales expenditure amount required for sales activities, number of sales successes, etc.

In step S303, the device 40 can check the ingredients and effects of the ingredients of the pharmaceutical company with which the CSO has a business history from the pharmaceutical business history.

In step S304, the device 40 may calculate a similar operating ratio, which is the ratio of drugs with similar ingredients that include the main ingredients of the medicine and contain ingredients for the same purpose as the effect of the main ingredient.

The device 40 includes the main ingredients of a specific pharmaceutical company's medicine among the medicines included in the CSO's medicine sales history, and calculates the similar sales ratio, which is the ratio of similar ingredient medicines containing ingredients for the same purpose as the effect of the main ingredient. It can be calculated.

By calculating the similar sales ratio, the device 40 analyzes medicines containing a specific main ingredient in the CSO company's medicine sales history, finds medicines containing similar ingredients with the same purpose as the ingredient, and determines the ratio. By calculating it, it is possible to check the proportion of medicines with similar ingredients that have the same effect as medicines containing a specific main ingredient among the medicines operated by CSO companies.

Accordingly, the device 40 can determine whether the CSO company conducted sales and sales activities for pharmaceuticals by focusing on specific ingredients or effects through the similar sales ratio.

In step S305, the device 40 can check the amount of sales expenditures and number of sales successes required for sales activities from the pharmaceutical sales history.

For drug sales and sales activities, CSO provides samples, product information sessions, cost discounts according to payment conditions, academic conference support, clinical trial support, product information sessions (multiple), post-marketing surveys, and confirmation of medical device performance before purchase. You can carry out business activities, including business activities, and spend the business expenditure amount required to carry out business activities.

In step S306, the device 40 may calculate the sales unit price by dividing the number of sales successes by the sales expenditure amount.

The device 40 can determine the sales efficiency of the CSO by calculating the sales unit price by dividing the sales expenditure amount by the number of successful sales, thereby confirming the cost incurred by the CSO per successful sales activity.

The sales unit price represents the average cost incurred for each sales activity and can be used to judge sales performance compared to cost. The lower the operating cost, the more cost-effective and higher profitability can be achieved.

In step S307, the device 40 can check the pharmaceutical company's sales budget from the pharmaceutical company's terminal 30.

The device 40 can receive information about the sales budget, which is the cost that the pharmaceutical company can spend on sales and sales activities of pharmaceuticals, from the pharmaceutical company's terminal 30, and match it with the pharmaceutical company to store the information about the sales budget.

In step S308, the device 40 may determine the number of commercially available pharmaceuticals for which sales activities can be carried out among pharmaceuticals containing major ingredients according to the difference value of the operating unit price in the sales budget.

The device 40 may calculate a difference value that is a value obtained by subtracting the operating cost from the operating budget. The device 40 determines the number of commercially available drugs to be higher as the difference value is larger, and determines the number of commercially available drugs to be lower as the difference value is smaller.

The device 40 determines the number of drugs that can be sold based on the sales budget of the pharmaceutical company and the sales price of the CSO, thereby allowing the pharmaceutical company to identify the number of drugs that can be entrusted with business and sales activities through the CSO. Through this, pharmaceutical companies can help develop and implement strategies to achieve drug sales goals according to their sales budget and sales price, and can utilize their budget effectively.

In step S309, the device 40 may determine the CSO's business index based on the similar business ratio, business unit price, and number of drugs available for business.

According to one embodiment, the device 40 determines the sales index of the CSO to be higher as the similar sales ratio is higher, the operating price is lower, and the number of drugs that can be sold is higher, and the lower the similar sales ratio is, the operating unit price is. The higher it is, the lower the number of drugs available for business, the lower the CSO's business index can be determined.

In step S310, the device 40 may generate CSO matching information based on the sales index.

According to one embodiment, the device 40 may generate CSO matching information including a list of CSOs generated by sorting CSOs in order of highest sales index, and transmit the CSO matching information to the pharmaceutical company's terminal 30.

The device 40 sorts CSOs in order of highest sales index, allowing pharmaceutical companies to easily compare the relative performance of each CSO company when selecting a CSO company.

The device 40 provides CSO matching information to the pharmaceutical company's terminal 30, so the pharmaceutical company can maximize business performance by identifying CSOs with high sales performance and select a CSO company to entrust the sales and sales activities of pharmaceuticals. It can help with decision-making. In addition, by preferentially assigning CSO companies with high sales performance to pharmaceutical companies, pharmaceutical companies can efficiently match with CSOs with high sales performance and strengthen competitiveness within CSO companies.

Figure 4 is a flowchart explaining the process of creating a pharmaceutical contract according to an embodiment.

In the process of providing the received ordering information to the pharmaceutical company's terminal 10, the device 40 creates a drug contract based on the ordering information and provides the drug contract company created along with the ordering information to the pharmaceutical company's terminal 10. The process can be performed.

Referring to FIG. 4, first, in step S401, the device 40 can check information on the drug to be ordered from the order information.

The device 40 can check information on the medicine to be ordered by the customer company from the order information.

In step S402, the device 40 may obtain the customer company's contact details including order information. For example, contact details may include, but are not limited to, information about email details for ordering, call records, text message details, etc.

In step S403, the device 40 can retrieve information about the drug to be ordered from the contact history and check the information of the pharmaceutical company corresponding to the order information.

The device 40 determines the product name of the drug to be ordered from the contact details, pharmaceutical company name, administration route, Ministry of Food and Drug Safety classification, KPI drug efficacy classification, main ingredient code, ingredient name, efficacy, drug code, dosage form, narcotic, AIC code, and medicine held by the manufacturer. By searching drug information, including inventory quantity, distribution method, etc., the customer can confirm the pharmaceutical company of the drug they wish to order.

In step S404, the device 40 can check whether there is an existing transaction with the pharmaceutical company corresponding to the drug to be ordered from the contact details.

As a result of searching for information on the drug to be ordered from the contact history, the device 40 determines that there is an existing transaction with the pharmaceutical company corresponding to the drug to be ordered, if there is information about the pharmaceutical company corresponding to the drug to be ordered, and places the order. If there is no information about the pharmaceutical company corresponding to the drug to be ordered, it can be determined that there is no existing transaction with the pharmaceutical company corresponding to the drug to be ordered.

In step S405, the device 40 may extract a pre-stored standard contract form if there is no existing transaction with the pharmaceutical company.

If, as a result of searching for information on the drug to be ordered from the contact history, there is no information on the pharmaceutical company corresponding to the drug to be ordered, the device 40 determines that there is no existing transaction with the pharmaceutical company corresponding to the drug to be ordered. You can.

The database of the device 40 may pre-store a standard contract form, which is a contract form to be filled out in the process of signing a contract to order a drug.

In step S406, the device 40 may create a drug contract using information on the drug to be ordered and information on the pharmaceutical company in the standard contract form.

The device 40 can automatically generate a pharmaceutical contract using the information on the drug to be ordered and the pharmaceutical company's information in the extracted standard contract form.

The device 40 automatically generates a contract for medicines, thereby reducing the inconvenience by not having to write the contract yourself every time a contract occurs. The automatic generation reduces the possibility of errors and allows the contract to be written accurately. .

In addition, the device 40 can maintain a consistent document format by creating a pharmaceutical contract based on a standard contract form, and enable the drug ordering and pharmaceutical company transaction process to proceed quickly and efficiently.

According to one embodiment, the device 40 automatically generates a drug contract according to a standard contract form, checks the drug contract, creates an interface that can be manually modified as needed, and provides it to the CSO's terminal 10. You can.

In step S407, if there is an existing transaction with the pharmaceutical company, the device 40 may extract an existing contract form from the contact history.

If, as a result of searching for information on the drug to be ordered from the contact history, there is information about the pharmaceutical company corresponding to the drug to be ordered, the device 40 may determine that an existing transaction exists with the pharmaceutical company corresponding to the drug to be ordered. .

If there is an existing transaction with the pharmaceutical company, the device 40 can extract the existing contract form included in the contact history.

In step S408, the device 40 can create a drug contract using information on the drug to be ordered and information on the pharmaceutical company in the existing contract form.

In step S409, the device 40 may compare the existing contract form and the standard contract form.

The device 40 can compare the existing contract form and the standard contract form and classify common parts of the existing contract form and the standard contract form and different parts between the existing contract form and the standard contract form.

In step S410, the device 40 displays the parts that are different from the existing contract form and the standard contract form according to the comparison result in the generated pharmaceutical contract with a first color, and displays the common parts with a second color that is different from the first color. You can. At this time, the first color and the second color may be set differently depending on the embodiment.

The device 40 can display different parts in the existing contract form and the standard contract form in a first color, allowing the user to quickly visually check which part of the contract has been changed. Accordingly, by detecting errors or missing information in advance, the accuracy of the document can be improved and consistency of following a standardized format can be maintained.

Figure 5 is a flowchart explaining the process of modifying a pharmaceutical contract according to an embodiment.

When the device 40 receives additional drug ordering information from the customer company's terminal 20, the device 40 can modify the drug contract.

Referring to FIG. 5, first, in step S501, the device 40 may compare order information and additional order information.

When the device 40 receives additional order information for a drug from the customer company's terminal 20, the device 40 can compare the order information and the additional order information to check whether the additional order information has changed from the order information.

In step S502, the device 40 may modify the pharmaceutical contract based on the comparison result with the ordering information.

The device 40 compares the ordering information and the additional ordering information, extracts the drug contract corresponding to the ordering information, modifies the portion in the drug contract where the additional ordering information has changed in the ordering information, and makes the ordering information and the additional ordering information the same. This part can be maintained in the pharmaceutical contract so that the pharmaceutical contract can be modified according to additional ordering information.

The device 40 can quickly detect changed contents and check whether additional ordering information needs to be modified. It dynamically modifies the pharmaceutical contract according to the ordering information to reflect the latest information and quickly applies the changed contents. Consistent documents can be maintained, and document consistency can be maintained by maintaining the same portions of ordering information and additional ordering information. Additionally, automated processes allow quick comparison and modification, improving efficiency compared to manual work.

Figure 6 is a flowchart for explaining the process of registering expenditure information according to an embodiment.

Referring to FIG. 6, first, in step S601, the device 40 may extract a pre-stored expense report form.

The expenditure report system was introduced in 2018 to increase transparency in drug and medical device transactions, and records the permitted economic benefits provided by drug suppliers, medical device manufacturers, etc. to medical personnel, pharmacists, etc. in accordance with the Pharmaceutical Affairs Act*?*Medical Device Act. This is a system that requires you to prepare and store related supporting materials.

In accordance with the obligation to prepare an expenditure report that requires CSOs to prepare and submit an expenditure report if they provide economic benefits, the device 40 obtains an expenditure report form from related websites that manage drug distribution such as the Korea Health Industry Development Institute and the Health Insurance Review and Assessment Service. can be collected and stored in a database.

Device 40 may extract pre-stored expense report forms from a database.

In step S602, the device 40 may create an expenditure report by applying expenditure information to the extracted expenditure report form.

In step S603, the device 40 can obtain information about the law on drug distribution and classify the first law currently in effect and the second law scheduled to be enforced among the laws.

For example, the device 40 may obtain information about the law on drug distribution from a law-related website and classify the first law currently in effect and the second law scheduled to be enforced among the laws.

For example, law-related websites may include, but are not limited to, websites of the National Law Information Center, Ministry of Health and Welfare, Ministry of Food and Drug Safety, and Korea Health Industry Development Institute.

In step S604, the device 40 may input the first law and the prepared expenditure report into a large language model (LLM) and output the first expenditure report.

At this time, a large language model (LLM) is a large-scale natural language processing model learned from numerous texts, and can use deep learning technology to learn the characteristics of text data and perform various natural language processing tasks.

One of the representative large-scale language models is GPT (Generative Pre-trained Transformer). GPT is based on a deep learning architecture called Transformer and has a structure with multiple layers. The GPT model first pre-trains a large amount of text data and can perform various natural language processing tasks based on the learned knowledge.

Large language models (LLMs) can understand complex patterns in text data by learning various language expressions, grammar, and meaning, and through this, process various languages, such as predicting the next word in a sentence or extracting meaningful information from a given sentence. work can be performed.

Large language models (LLMs) can be used in a variety of application fields such as automatic summarization, translation, question answering, and text generation, and examples include, but are not limited to, the GPT series, BERT, XLNet, etc.

According to one embodiment, device 40 may pre-train a large language model (LLM) to update the expense report based on the law.

The device 40 may input the first law and expenditure report into a large language model (LLM) and preprocess the input legal text and expenditure report text into a form that the model can understand. For example, preprocessing may include, but is not limited to, tokenization, sentence separation, special character removal, etc.

Device 40 may configure legal text and expense report text as input to the model.

The device 40 can enhance language understanding of legal text by utilizing a pre-trained large language model (LLM), and the model can learn legal terms, grammar, context, etc.

Large language models (LLMs) can understand legal text and perform inferences based on what the user requests. For example, you can identify legal provisions needed to update expense reports or identify new regulations or changes.

Large Language Models (LLMs) can generate the content needed to update expenditure reports according to law.

Device 40 may generate an updated expense report based on the model's prediction results. Large Language Model (LLM) can modify or add text according to the input laws and expenditure reports and generate new expenditure reports based on them.

The device 40 may input the first law and the prepared expenditure report into a large language model (LLM) and output the first expenditure report with the expenditure report modified according to the first law.

In step S605, the device 40 may input the second law and the prepared expenditure report into a large language model (LLM) and output the second expenditure report.

The device 40 may input the second law and the prepared expenditure report into a large language model (LLM) and output a second expenditure report with the expenditure report modified according to the second law.

In step S606, the device 40 displays the expenditure report in the first area of the screen of the CSO's terminal 10, displays the first expenditure report in the second area, and displays the second expenditure report in the third area. can do.

At this time, the screen of the CSO's terminal 10 may include a first area, a second area, and a third area. The sizes and shapes of the first area, second area, and third area may be set differently depending on the embodiment.

The device 40 provides the CSO with the prepared expenditure report, the first report prepared according to the law currently in force, and the second report prepared according to the law scheduled to be implemented at once to the CSO, so as to identify the expenditure report prepared according to the time when the law is applied. By doing so, CSOs can identify changing laws in the process of conducting and reporting business activities and perform business activities based on valid laws depending on the reporting period. It ensures that CSOs can secure the latest information whenever laws change, help them understand changed regulations, and accurately prepare reports that must be submitted in response to legal changes that occur during business activities.

In other words, device 40 can help CSOs more appropriately perform legally required reporting and sales activities and strengthen legal compliance.

Device 40 may display different portions of the expense report, the first expense report, and the second expense report in different colors. Device 40 uses different colors in different areas to visually represent differences in the expense report and related information, allowing changes to be quickly identified.

In step S607, when any one of the colored parts in the first expenditure report is selected, the device 40 may extract the law corresponding to the selected part among the first laws and display it in a pop-up form in the second area. there is. At this time, the size, location, and shape of the pop-up form may be set differently depending on the embodiment.

In step S608, when any one of the colored parts in the second expenditure report is selected, the device 40 may extract the law corresponding to the selected part of the second law and display it in a pop-up form in the third area. there is. At this time, the size, location, and shape of the pop-up form may be set differently depending on the embodiment.

The device 40 immediately provides the legal content for the selected part in a pop-up form, allowing the CSO company to quickly understand the legal content related to the expenditure report. In addition, because it is displayed in a pop-up form, CSOs can immediately review legal information without blocking work, and because the legal content for the selected part is presented directly, interpretation errors can be prevented and accurate information can be delivered. Additionally, the device 40 can provide CSO companies with the opportunity to compare and learn legal content with actual reports.

In step S609, the device 40 may check the storage period of the expenditure information based on the law, and store the expenditure information including the expenditure report, the first expenditure report, and the second expenditure report according to the storage period.

The device 40 can ensure compliance by adhering to legally mandated storage periods and retain data for the legally required period, allowing CSO companies to retain information that can be submitted when necessary.

Figure 7 is a flow chart to explain a process for providing a notification of leakage of an order report according to an embodiment.

Referring to FIG. 7, first, in step S701, the device 40 may obtain order details including order information from the CSO's terminal 10.

At this time, the order details may include all order information received during a preset period. The preset period may be set differently depending on the embodiment.

In step S702, the device 40 generates an order report based on the order information, pharmaceutical company information, and drug information included in the order details, and uploads it by inserting a security phrase generated differently for each order report.

According to one embodiment, the device 40 may generate a security phrase that is generated differently for each order report and display the generated security phrase on each order report.

The device 40 displays a security phrase on each order report, so that the dynamic security phrase inserted into each order report can increase the integrity and reliability of the document, and each report can be identified through a security phrase generated differently for each order report. You can.

For example, the device 40 may generate a different security phrase for each report, and each security phrase may use a randomly generated string or number combination, but is not limited to this.

For example, the device 40 may generate a security phrase by combining alphabets, numbers, special characters, etc.

By uploading an ordering report with a security phrase inserted onto the platform, the device 40 can allow other CSO companies, pharmaceutical companies, customer companies, etc. to view the ordering report through the platform and encourage participation in the platform.

In step S703, when one order report is selected from the pharmaceutical company's terminal 30 among the uploaded order reports, the device 40 may display an order report with the numbers included in the order report modified to be within a preset range. .

For example, if the order quantity of the drug included in the order report is 2010 and the preset range is 20, when the order report from the first pharmaceutical company is selected, the device 40 modifies the order quantity from the first pharmaceutical company to 2020 and creates the order report. can be displayed.

For example, if the order quantity of the medicine included in the order report is 2010 and the preset range is 20, when the order report from the second pharmaceutical company is selected, the device 40 modifies the order quantity from the second pharmaceutical company to 2015 and creates the order report. can be displayed.

In step S704, the device 40 collects uploaded order reports for a preset period, and determines whether there is a leaked order report among the collected order reports that has duplicate security phrases or is similar in value within a preset range. . At this time, the preset period may be set differently depending on the embodiment. At this time, the preset range may be set differently depending on the embodiment.

In step S705, if a leaked order report exists, the device 40 may provide a leakage notification to the CSO's terminal 10.

The device 40 may determine a report that is similar to an existing uploaded ordering report as having overlapping security phrases or a numerical value within a preset range as a leaked ordering report.

The device 40 can identify a leaked order report by detecting duplication of security phrases and similarity of numbers, and when a leaked order report is found, it can provide a leak notification to the CSO's terminal 10.

Figure 8 is an exemplary diagram of the configuration of a device according to an embodiment.

Device 40 according to one embodiment includes a processor 41 and memory 42. The device 40 according to one embodiment may be the server or terminal described above. The processor 41 may include at least one device described above with reference to FIGS. 1 to 7 or may perform at least one method described with reference to FIGS. 1 to 7 . The memory 42 may store information related to the above-described method or store a program in which the above-described method is implemented. Memory 42 may be volatile memory or non-volatile memory.

The processor 41 can execute programs and control the device 40. The code of the program executed by the processor 41 may be stored in the memory 42. The device 40 is connected to an external device (eg, a personal computer or a network) through an input/output device (not shown) and can exchange data.

The embodiments described above may be implemented with hardware components, software components, and/or a combination of hardware components and software components. For example, the devices, methods, and components described in the embodiments may include, for example, a processor, a controller, an arithmetic logic unit (ALU), a digital signal processor, a microcomputer, and a field programmable gate (FPGA). It may be implemented using one or more general-purpose or special-purpose computers, such as an array, programmable logic unit (PLU), microprocessor, or any other device capable of executing and responding to instructions. A processing device may execute an operating system (OS) and one or more software applications that run on the operating system. Additionally, a processing device may access, store, manipulate, process, and generate data in response to the execution of software. For ease of understanding, a single processing device may be described as being used; however, those skilled in the art will understand that a processing device includes multiple processing elements and/or multiple types of processing elements. It can be seen that it may include. For example, a processing device may include a plurality of processors or one processor and one controller. Additionally, other processing configurations, such as parallel processors, are possible.

The method according to the embodiment may be implemented in the form of program instructions that can be executed through various computer means and recorded on a computer-readable medium. The computer-readable medium may include program instructions, data files, data structures, etc., singly or in combination. Program instructions recorded on the medium may be specially designed and configured for the embodiment or may be known and available to those skilled in the art of computer software. Examples of computer-readable recording media include magnetic media such as hard disks, floppy disks, and magnetic tapes, optical media such as CD-ROMs and DVDs, and magnetic media such as floptical disks. -Includes optical media (magneto-optical media) and hardware devices specifically configured to store and execute program instructions, such as ROM, RAM, flash memory, etc. Examples of program instructions include machine language code, such as that produced by a compiler, as well as high-level language code that can be executed by a computer using an interpreter, etc. The hardware devices described above may be configured to operate as one or more software modules to perform the operations of the embodiments, and vice versa.

Software may include a computer program, code, instructions, or a combination of one or more of these, which may configure a processing unit to operate as desired, or may be processed independently or collectively. You can command the device. Software and/or data may be used on any type of machine, component, physical device, virtual equipment, computer storage medium or device to be interpreted by or to provide instructions or data to a processing device. , or may be permanently or temporarily embodied in a transmitted signal wave. Software may be distributed over networked computer systems and stored or executed in a distributed manner. Software and data may be stored on one or more computer-readable recording media.

Although the embodiments have been described with limited drawings as described above, those skilled in the art can apply various technical modifications and variations based on the above. For example, the described techniques are performed in a different order than the described method, and/or components of the described system, structure, device, circuit, etc. are combined or combined in a different form than the described method, or other components are used. Alternatively, appropriate results may be achieved even if substituted or substituted by an equivalent.

Therefore, other implementations, other embodiments, and equivalents of the claims also fall within the scope of the following claims.

Claims (3)

In a method performed by a device,
Receiving a sales request including drug information from a pharmaceutical company's terminal, and generating CSO matching information for drug sales activities based on the drug information;
Providing the drug information to the terminal of the CSO corresponding to the CSO matching information;
Providing the drug information to terminals of customer companies including hospitals and pharmacies;
Receiving pharmaceutical order information from the customer company's terminal;
Providing the received order information to the pharmaceutical company's terminal;
When delivery of the medicine corresponding to the order information is completed, determining a fee for the CSO; and
Generating expenditure information based on the drug information, the ordering information, and the fee information, and registering the expenditure information,
In the step of providing the received order information to the pharmaceutical company's terminal,
Generating a drug contract based on the ordering information, and providing the generated drug contract along with the ordering information to the pharmaceutical company's terminal,
The steps for creating the pharmaceutical contract are:
Confirming the information of the drug to be ordered from the ordering information,
Obtaining customer company contact details including the ordering information,
Retrieving information on the drug to be ordered from the contact details, and confirming information on the pharmaceutical company corresponding to the order information;
Checking whether there is an existing transaction with the pharmaceutical company corresponding to the drug to be ordered from the contact details,
If there is no existing transaction with the pharmaceutical company, extracting a pre-stored standard contract form,
Creating a pharmaceutical contract using the information of the drug to be ordered and the pharmaceutical company's information in the standard contract form,
If there is an existing transaction with the pharmaceutical company, extracting an existing contract form from the contact history,
Creating a drug contract using the information of the drug to be ordered and the pharmaceutical company's information in the existing contract form,
Comparing the existing contract form and the standard contract form, and
In the generated pharmaceutical contract, a step of displaying parts that are different from the existing contract form and the standard contract form according to the comparison result with a first color, and displaying common parts with a second color different from the first color,
When receiving additional ordering information for medicines from the customer company's terminal, further comprising modifying the medicine contract,
The steps to modify the pharmaceutical contract are:
Comparing the ordering information and additional ordering information, and
Comprising the step of modifying the pharmaceutical contract based on a comparison result of the ordering information,
The step of registering the expenditure information is,
extracting pre-saved expense report forms;
preparing an expenditure report by applying the expenditure information to the extracted expenditure report form;
Obtaining information on laws on drug distribution and classifying the first law currently in effect and the second law scheduled to be implemented among the above laws,
Inputting the first law and the prepared expenditure report into a large language model (LLM) previously trained to update the expenditure report based on the law and outputting a first expenditure report;
Inputting the second law and the prepared expenditure report into a large language model (LLM) previously trained to update the expenditure report based on the law and outputting a second expenditure report;
Displaying the expenditure report in a first area of the screen of the CSO terminal, displaying the first expenditure report in a second area, and displaying the second expenditure report in a third area, wherein the expenditure report, the first marking different parts of the first expenditure report and the second expenditure report in different colors;
When any one of the colored parts in the first expenditure report is selected, extracting the law corresponding to the selected part among the first laws and displaying it in a pop-up form in the second area,
When any one of the colored parts in the second expenditure report is selected, extracting the law corresponding to the selected part among the second laws and displaying it in a pop-up form in the third area, and
Confirming a storage period of the expenditure information based on the law, and storing the expenditure information including the expenditure report, the first expenditure report and the second expenditure report according to the storage period,
Obtaining order details including the order information from the CSO's terminal;
Generating an ordering report based on the ordering information, pharmaceutical company information, and drug information included in the ordering details, inserting and uploading a differently generated security phrase for each ordering report;
When one of the uploaded order reports is selected from the pharmaceutical company's terminal, displaying an order report with values included in the order report modified to be within a preset range;
Collecting uploaded order reports during a preset period, and determining whether there are leaked order reports among the collected order reports with overlapping security phrases or similar numerical values within a preset range; and
If the leaked order report exists, further comprising providing a leakage notification to the CSO's terminal,
Method of providing automated platform service for reporting processing of sales and expenditure resolutions by user for pharmaceutical distribution. According to paragraph 1,
The step of generating the CSO matching information is,
Confirming the ingredients included in each pharmaceutical company's medicine from the medicine information, and determining as the main ingredient the ingredient that satisfies preset standards among the ingredients included in the medicine;
Obtaining pharmaceutical sales history from the CSO's terminal,
Confirming the ingredients and effects of the ingredients of the pharmaceutical company with which the CSO has a business history from the pharmaceutical business history,
Calculating a similar sales ratio, which is the ratio of drugs with similar ingredients that include the main ingredient among the medicines included in the pharmaceutical sales history and contain ingredients for the same purpose as the effect of the main ingredient,
Confirming the amount of sales expenditures and number of sales successes required for sales activities from the pharmaceutical sales history,
Calculating a sales unit price by dividing the number of sales successes by the sales expenditure amount,
Confirming the pharmaceutical company's sales budget from the pharmaceutical company's terminal,
Determining the number of drugs available for business that can proceed with business activities among drugs containing the main ingredients according to the difference value of the business unit price in the business budget,
Determining the sales index of the CSO based on the similar sales ratio, sales price, and number of drugs available for business, and
Including generating CSO matching information based on the sales index,
Method of providing automated platform services for reporting processing of sales and expenditure resolutions by user for pharmaceutical distribution. delete